

University of Groningen

## **International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma**

Lee, Anne W; Ng, Wai Tong; Pan, Jian Ji; Chiang, Chi-Leung; Poh, Sharon S; Choi, Horace C; Chan Ahn, Yong; AlHussain, Hussain; Corry, June; Grau, Cai

*Published in:*  
International Journal of Radiation Oncology, Biology, Physics

*DOI:*  
[10.1016/j.ijrobp.2019.06.2540](https://doi.org/10.1016/j.ijrobp.2019.06.2540)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Final author's version (accepted by publisher, after peer review)

*Publication date:*  
2019

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Lee, A. W., Ng, W. T., Pan, J. J., Chiang, C-L., Poh, S. S., Choi, H. C., Chan Ahn, Y., AlHussain, H., Corry, J., Grau, C., Grégoire, V., Harrington, K. J., Hu, C. S., Kwong, D. L., Langendijk, J. A., Le, Q. T., Lee, N. Y., Lin, J. C., Lu, T. X., ... Wee, J. T. (2019). International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology, Biology, Physics*, 105(3), 567-580. <https://doi.org/10.1016/j.ijrobp.2019.06.2540>


### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



## International Guideline on Dose Prioritization and Acceptance Criteria in Radiotherapy Planning for Nasopharyngeal Carcinoma

Anne W. Lee, FRCR, Wai Tong Ng, FRCR, Jian Ji Pan, MD, Chi-Leung Chiang, FRCR, Sharon S. Poh, FRCR, Horace C. Choi, PhD, Yong Chan Ahn, MD, Hussain AlHussain, FRCPC, June Corry, FRANZCR, Cai Grau, MD, Vincent Grégoire, MD, PhD, Kevin J. Harrington, FRCR, Chao Su Hu, MD, Dora L. Kwong, FRCR, Johannes A. Langendijk, MD, Quynh Thu Le, MD, Nancy Y. Lee, MD, Jin Ching Lin, MD, Tai Xiang Lu, MD, William M. Mendenhall, MD, Brian O'Sullivan, FRCPC, Enis Ozyar, MD, Lester J. Peters, FRANZCR, David I. Rosenthal, MD, Giuseppe Sanguineti, MD, Yoke Lim Soong, FRCR, Yungan Tao, MD, Sue S. Yom, MD, Joseph T. Wee, FRCR

PII: S0360-3016(19)33428-5

DOI: <https://doi.org/10.1016/j.ijrobp.2019.06.2540>

Reference: ROB 25828

To appear in: *International Journal of Radiation Oncology • Biology • Physics*

Received Date: 25 October 2018

Revised Date: 12 June 2019

Accepted Date: 25 June 2019

Please cite this article as: Lee AW, Ng WT, Pan JJ, Chiang C-L, Poh SS, Choi HC, Chan Ahn Y, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT, International Guideline on Dose Prioritization and Acceptance Criteria in Radiotherapy Planning for Nasopharyngeal Carcinoma, *International Journal of Radiation Oncology • Biology • Physics* (2019), doi: <https://doi.org/10.1016/j.ijrobp.2019.06.2540>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **International Guideline on Dose Prioritization and Acceptance Criteria in Radiotherapy Planning for Nasopharyngeal Carcinoma**

Anne W Lee FRCR<sup>\*1</sup>, Wai Tong Ng FRCR<sup>\*2</sup>, Jian Ji Pan MD<sup>3</sup>, Chi-Leung Chiang FRCR<sup>1</sup>, Sharon S Poh FRCR<sup>4</sup>, Horace C Choi PhD<sup>5</sup>, Yong Chan Ahn MD<sup>6</sup>, Hussain AlHussain FRCPC<sup>7</sup>, June Corry FRANZCR<sup>8#</sup>, Cai Grau MD<sup>9#</sup>, Vincent Grégoire MD, PhD<sup>10#</sup>, Kevin J. Harrington FRCR<sup>11</sup>, Chao Su Hu MD<sup>12</sup>, Dora L Kwong FRCR<sup>13#</sup>, Johannes A. Langendijk MD<sup>14</sup>, Quynh Thu Le MD<sup>15#</sup>, Nancy Y Lee MD<sup>16</sup>, Jin Ching Lin MD<sup>17</sup>, Tai Xiang Lu MD<sup>18</sup>, William M Mendenhall MD<sup>19</sup>, Brian O'Sullivan FRCPC<sup>20#</sup>, Enis Ozyar MD<sup>21</sup>, Lester J Peters FRANZCR<sup>22</sup>, David I. Rosenthal MD<sup>23</sup>, Giuseppe Sanguineti MD<sup>24</sup>, Yoke Lim Soong FRCR<sup>4#</sup>, Yungan Tao MD<sup>25</sup>, Sue S Yom MD<sup>26</sup> and Joseph T Wee FRCR<sup>\*4</sup>.

\*These 3 authors contributed equally.

<sup>1</sup> Department of Clinical Oncology, University of Hong Kong Shenzhen Hospital and University of Hong Kong, CHINA

<sup>2</sup> Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, HONG KONG

<sup>3</sup> Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, CHINA.

<sup>4</sup> Division of Radiation Oncology, National Cancer Centre Singapore. Oncology ACP, Duke-NUS Medical School, SINGAPORE

<sup>5</sup> Department of Clinical Oncology, University of Hong Kong, HONG KONG

<sup>6</sup> Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA

<sup>7</sup> Department of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, SAUDI ARABIA

<sup>8</sup> Radiation Oncology, GenesisCare, St. Vincent's Hospital, Melbourne, Victoria, AUSTRALIA.

<sup>9</sup> Department of Oncology, Aarhus University Hospital, Aarhus, DENMARK

<sup>10</sup> Center for Molecular Imaging, Oncology and Radiotherapy, Université Catholique de Louvain, Brussels, BELGIUM and Department of Radiation Oncology, Centre Léon Bérard, Lyon, FRANCE

<sup>11</sup> The Royal Marsden / The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre, London, UK

<sup>12</sup> Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai CHINA

<sup>13</sup> Department of Clinical Oncology, University of Hong Kong and Queen Mary Hospital, HONG KONG

<sup>14</sup> Department of Radiotherapy, University Medical Center Groningen, University of Groningen, Groningen, THE NETHERLANDS

<sup>15</sup> Department of Radiation Oncology, Stanford University, NRG Oncology and HNCIG, CA, USA

<sup>16</sup> Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, NY, USA

<sup>17</sup> Department of Radiation Oncology, Taichung Veterans General Hospital, National Yang-Ming University, Taipei, TAIWAN

<sup>18</sup> Department of Radiation Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, CHINA

<sup>19</sup> Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA

<sup>20</sup> Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, CANADA

<sup>21</sup> Department of Radiation Oncology, Acibadem University School of Medicine, Istanbul, TURKEY

<sup>22</sup> Peter MacCallum Cancer Centre, Melbourne, Victoria, AUSTRALIA

<sup>23</sup> Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

<sup>24</sup> Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, ITALY

<sup>25</sup> Department of Radiation Oncology, Institut Gustave Roussy, Paris-Saclay University, Villejuif, FRANCE

<sup>26</sup> Department of Radiation Oncology, University of California – San Francisco, San Francisco, CA, USA

#Representative of member organizations in the Head and Neck Cancer International Group (HNCIG)

**Corresponding author:**

Joseph T Wee FRCR

Duke-NUS Medical School, Singapore

Division of Radiation Oncology,

National Cancer Centre Singapore

11 Hospital Drive, 169610

SINGAPORE

E-mail: joseph.wee.t.s@singhealth.com.sg

### **Keywords**

Nasopharyngeal carcinoma, clinical target volume (CTV), gross target volume (GTV), guideline, delineation, radiotherapy planning

### **Funding source**

None to declare

### **Ethical considerations**

None to declare

**Conflicts of Interest**

Dr. Kevin Harrington reports grants, personal fees and non-financial support from ELEKTA, during the conduct of the study. Dr Langendijk reports that the department of radiation oncology has research agreements with IBA, MIRADA and Raysearch. He has received a fee from IBA for giving a presentation at a symposium and giving consultancy. This had been paid to UMCG research B.V.. Dr. Nancy Lee reports being an Advisory Board/Consultant for Merck, Merck Serono, Pfizer, Sanofi Aventis, and Lily. Dr. Quynh Le reports grants from Redhill, other from BMS advisory board, outside the submitted work. Dr. Yungan Tao reports grants and non-financial support from MSD, non-financial support and other from Merck serono, grants from Debiopharm, grants, non-financial support and other from Onxeo, outside the submitted work. Dr. Sue Yom reports grants from Bristol-Myers Squibb, grants from Merck, grants from Genentech, outside the submitted work.

All the other authors declare no conflicts of interests

**Author's contributions**

AWL, WTN and JTW conceived of the idea, developed and executed the consensus development. All authors participated in the consensus development. AWL, WTN, JTW, SSP, CLC, HCC and SY were involved in the writing phase of the manuscript. All authors reviewed and approved the final manuscript.

**Supplementary Material**

Supplementary Table 1: Initial recommendations, % agreement and alternative suggestions.

Supplementary Table 2: Quality of evidence and definitions

Supplementary Appendix 1: Literature Search Summary

ACCEPTED MANUSCRIPT

# **International Guideline on Dose Prioritization and Acceptance Criteria in Radiotherapy Planning for Nasopharyngeal Carcinoma**

## **Keywords**

Nasopharyngeal carcinoma, clinical target volume (CTV), gross target volume (GTV), guideline, delineation, radiotherapy planning

## **Funding source**

None to declare

## **Ethical considerations**

None to declare

**Summary**

This guideline is the result of an international consensus to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and organs at risk for nasopharyngeal carcinoma.

## **Abstract**

### *Purpose*

The treatment of nasopharyngeal carcinoma (NPC) requires high radiation doses. The balance of the risks of local recurrence due to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformity is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the ALARP (As Low As Reasonably Practicable) principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference.

### *Methods*

A literature search on dose tolerances and normal tissue complications following treatment for NPC was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications and/or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then re-circulated to the whole panel for review and re-consideration. Based on the comments of the panel, a refined second proposal was re-circulated to the same panel. The current guideline was based on majority voting following repeated iteration for final agreement.

### *Results*

Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed.

### *Conclusions*

Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and patient's acceptance of optimal balance of risk.

## Introduction

Radiation therapy (RT) for nasopharyngeal carcinoma (NPC) presents a unique challenge due to the anatomical proximity of target volumes to critical organs at risk (OARs). Although NPC, especially the classical non-keratinizing type, is relatively radiosensitive, high doses are generally needed for eradication of gross tumor and the therapeutic margin for optimal tumor control is notoriously narrow. Even in the contemporary era of intensity-modulated radiotherapy (IMRT) with extensive use of concurrent chemotherapy, dosimetric inadequacy enforced by dose constraints on OARs remains one of the most important independent factors affecting treatment outcome. It is often difficult to achieve the optimal balance and trade-off between risks of local recurrence due to inadequate tumor coverage versus potential serious late complications; this results from the inevitably high doses to OARs in the case of advanced tumors with extensive locoregional infiltration [1]. Decisions on prioritization vary substantially depending on different philosophies.

The advent of newer planning and treatment delivery technologies has led to an evolving capability to maximize dose conformity. Although there is little doubt that IMRT is superior in improving tumour control and reducing toxicities when compared with 2DRT, there is marked variation in the toxicities reported. In the trial by Peng et al. [2], the incidence of temporal lobe necrosis was still as high as 13.1% and optic nerve/chiasm injury was 1.6% in the IMRT arm; in contrast, other studies have shown that it is possible to achieve similar local control with substantially lower rates of neurological toxicity, such as a temporal lobe necrosis rate of 0.2% [3].

Standardizing the appropriate delineation of tumour targets for different dose levels, dose prioritization for tumour targets and the various OARs, and acceptance criteria for each parameter is fundamental for future study and progress. Unfortunately, accurate data on the tolerance doses of critical OARs remain scanty. There is also marked variation in the philosophy and practice amongst different institutions and clinicians with regards to the order of prioritisation and the exact maximum acceptable doses for the different OARs.

Through a process of iterative development amongst international experts, we aimed to provide clinicians with a reference tool for treatment planning for NPC. Twenty-six

contributors from major centres in Asia, Australia, North America, Middle East and Europe previously provided input into the publication of “xxxx” [4]. To address issues that could not be covered in the previous guideline, our goal for this document was to provide a practical reference to assist clinicians in deciding on the optimal RT planning process for NPC and the best possible compromise for difficult cases.

## Methodology

The following processes were used for evidence searching and development of the guideline:

Firstly, an initial literature search on NPC-specific late complications was performed on December 2017 in PubMed using the following search terms: ("intensity-modulated radiation therapy" OR "intensity-modulated radiotherapy" OR IMRT) nasopharyngeal ("late toxicity" OR "temporal lobe" OR brainstem OR visual OR optic OR eye OR hearing OR ear)

Published treatment guidelines and dose constraints by various centers were also reviewed. This formed the initial set of planning dose prioritization and acceptance criteria for voting based on a modified Delphi process [5-18]. A preliminary set of proposed variants for planning dose prioritization and acceptance criteria was then drafted. In order to provide a pragmatic reference, both a “goal” OAR constraint and a variation acceptable for treatment in challenging situations (i.e. maximum acceptance criteria (MAC)) were listed.

Secondly, a panel of international experts was convened to develop the guideline. To ensure appropriate recommendations with international representation, criteria were set to include only members with publications on treatment outcome (tumour control and toxicity), and/or extensive experience specific to NPC in major academic centres from different parts of the world (including Asia, Middle East/Mediterranean Region, Oceania, Europe and North America).

We used a modified Delphi process for developing the final guideline: the preliminary proposal, together with previously published guidelines and protocols (Table 1), was circulated among international experts for initial voting and comments. The initial percentage of agreement on the proposed criteria and the alternative views are shown in the Appendix

(Supplementary Table 1). The exact votes submitted were anonymized, while summary of this initial voting and different opinions and proposed variants expressed by members were circulated to the whole panel for review and re-consideration. Based on the exchanged comments and supporting data, a refined second proposal was drafted after repeated iteration among the panel members, and circulated for another round of voting. The current, finalized guideline summarized in Table 2 was based on majority views.

In order to identify additional evidence published since the initial manuscript was finalized, a new literature search using the same search terms was conducted in May 2019 to ensure comprehensiveness of this review including the latest published evidence. 256 articles were identified; using the PRISMA checklist approach, 211 were excluded after initial screening of the abstracts. Of the 35 potentially relevant articles reviewed, 11 were excluded as they were found to be irrelevant to the subject of this study. Among the 24 relevant articles, 18 were cited in this manuscript as they provided specific recommendations on OAR dose constraints based on the latest updated data from the institute.

A figure illustrating the literature search summary is added in Supplementary Appendix I.

No major inconsistencies or discrepancies with our recommendations were found except for one very recent article on the dose constraint for the brainstem [19]. This information was circulated to the panel and a brief description of the findings was added to the guideline text, but the unanimous feedback from panel members was that this could not be recommended as practice-changing without further validation.

The strength of the recommendations was rated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system (Supplementary Table 2) [20]. The GRADE level of evidence assigned for each OAR was initially discussed and drafted by the three senior authors; and circulated to all the authors as part of the manuscript review. There were no objections or changes to suggested GRADE assignments. The evidence on dose constraints was largely derived from retrospective studies. The percentages of agreement among the panel members in the final vote (together with the exact number of votes) were listed in the manuscript and Table 2. The alternative constraints suggested by dissenting experts were also shown to illustrate existing variations and the potential range for future consideration.

## Results and Discussion on the Recommendations

Before proceeding to setting dose prioritization and constraints, appropriate contouring of various structures is the first fundamental requirement. An international guideline on contouring of clinical tumour target volumes has been published previously [4]. Many authors in this current guideline also participated in the development of guidelines on contouring of organs at risk specifically for NPC [21] and head and neck cancers [22] which serve as useful references. We recommend that a planning risk volume (PRV) be delineated around critical organs to account for set-up variability. While this set-up variability varies among different institutions, a margin of not less than 2mm was generally recommended based on the study by Van Herk [23].

### *Prioritisation of dose constraints*

A study by Yao et al [24] in a cohort of NPC patients with gross tumour volume exceeding 60 cm<sup>3</sup>, showed that the prescribed mean doses to brainstem PRV and optic chiasm PRV were 68.13 Gy ( $\pm$  4.74 Gy) and 66.54 Gy ( $\pm$  8.62 Gy), respectively, which were far higher than the usual recommended dose constraints for these OARs. With IMRT treatment planning, setting the appropriate prioritization levels for different structures is fundamental for achieving the desired optimization of dose distribution. The general principle is to achieve full tumoricidal doses to the whole tumour target within the maximum tolerance dose of critical OARs. However, in the frequent situations in which a trade-off must be made, more than 90% of the expert panel agreed that the priority should be given to the critical OAR(s) to avoid potentially lethal or highly morbid sequelae.

When the treatment plan is unable to give adequate tumor target coverage and meet the dose constraints for priority 1 OARs, we suggest either adaptive re-planning or consideration of induction chemotherapy. A recent randomized study by Yang et al suggests that the strategy of restricting full therapeutic dose to the MRI-defined volume that remains after induction chemotherapy, while ensuring that the pre-induction chemotherapy volume receives at least an intermediate dose (64 Gy) appears not to compromise 3-year local, regional and distant control or overall survival but served to reduce late toxicities and overall health status in a

cohort of 212 NPC patients [25]. Whether these results will continue to hold should an even lower dose be used (to meet critical OAR constraints) remains to be seen.

There was unanimous agreement that Priority 1 should include the brainstem, spinal cord and optic chiasm, as damage to these serially arranged structures can result in catastrophic morbidity, and even mortality. Bilateral blindness due to damage to optic chiasm and/or both optic nerves is such a debilitating complication that there is universal agreement that at least the optic nerve on the less involved side should be included as Priority 1 for dose constraint. However, we would consider exceeding the commonly recommended MAC for the ipsilateral optic nerve (lowering to Priority 3) if this is unavoidable to achieve adequate doses to cover the tumour target, provided the patient consents to an increased risk of unilateral partial or complete loss of sight. The latter entails a careful explanation of the relative importance of the different components and trade-offs during the decision process.

There was also unanimous agreement that Priority 2 should include tumour Planning Target Volume (PTV). There was, however, variation as to whether the priority for Gross Tumour Volume (GTV) should be raised to Priority 1 because, although it may still not be feasible to achieve minimum  $D_{98\%}$  of the prescribed dose to 100% of the GTV, there would at least be greater attempts to achieve the highest feasible dose. Under such circumstances, the options for the most suitable compromise should be discussed with the patient.

We recommend that the temporal lobes be included under Priority 2 as temporal lobe necrosis (TLN) can lead to serious disability and mortality. The study by Lam et al. [26] showed that 54% of patients progressed to grade 4 severity at 5 years after the diagnosis of TLN (asymptomatic and symptomatic) and 5-year overall survival was only 35%. However, there was variation in the level of priority accorded for this structure.

There was also complete agreement that normal tissues in the oral cavity, post-cricoid pharynx, esophagus and glottic larynx should be assigned to Priority 4. There were variations as to whether the other structures should be set at Priority 3 or Priority 4. We recommend that the brachial plexus, pituitary gland, eyeball and lens be included as Priority 3; while cochlea, mandible and temporo-mandibular joints, thyroid, parotid and submandibular glands should be included under Priority 4.

Readers may wish to familiarize themselves with the DAHANCA Radiotherapy Guidelines 2013 [14]. DAHANCA has a long history of producing RT guidelines, with dose-volume constraints and rules for prioritization. Instead of using two terms for constraints, “Desirable” and “Acceptable”, they distinguish between OAR dose and PRV dose. There are also some differences in the priority listing. In general, DAHANCA ranks PTV coverage lower than critical serial OARs, to allow compromises where the margins are tight.

### ***The desired dose and acceptance criteria for different structures***

#### ***Brainstem***

The QUANTEC review [27] recommended that a small volume of brainstem (1-10 mL) may be irradiated to a maximum dose of 59 Gy using dose fractionation  $\leq 2$  Gy and a  $D_{\max} < 64$  Gy with a point dose  $< 1$  cc. Two studies have been reported from Sun Yat-Sen Cancer Center to assess brainstem injury incurred by doses higher than that recommended by QUANTEC. The study (n=1544) by Li et al. [28] showed 59% of patients received a  $D_{\max} \geq 54$  Gy, and 25% received  $\geq 64$  Gy, of whom two developed brainstem necrosis; both had received a  $D_{\max}$  dose  $\geq 76.4$  Gy and a  $V_{55} \geq 3.8$  cc. Their most recent analysis by Huang et al. [19] on 6264 NPC patients showed that patients with  $D_{\max} \geq 67.4$  Gy (equivalent dose in 2-Gy fractions {EQD2}) had significantly higher incidence of brainstem injury (odds ratio = 25.29, 95% CI: 8.63–74.14;  $P < 0.001$ ) than those with lower dose.  $D_{\max}$  of 67.4 Gy (EQD2) was recommended as the dose constraint for brainstem, but the authors also concluded that further studies are needed to validate their findings. On the other hand, Yao et al. [29] reported an alarming incidence rate of 2.8% at 5 years in a cohort of 327 NPC patients. Among the 8 patients with brainstem injury, seven (one fatal and one hemiplegic) had  $D_{\max}$  and  $D_{0.1cc} \geq 63.38$  Gy and 60.89 Gy, respectively.

Other studies showed that the volume of brainstem with high dose is also important: Uy et al. [30] reported a case of brainstem necrosis with a  $V_{54}$  of 4.7 cc.; Debus et al. [31] showed that a  $V_{50} > 5.9$  cc,  $V_{55} > 2.7$  cc, and  $V_{60} > 0.9$  cc were associated with brainstem toxicity. Schoenfeld et al. [32] further recommended to restrict the  $V_{55}$  to  $< 0.1$  cc.

In view of the potential devastating consequence and risk of serious medico-legal implications by brainstem injury, while a higher dose ( $D_{\max}$  of 67.4 Gy) may be discussed as an option for patients with tumors encroaching the brainstem, a more conservative dose acceptance criterion was preferred among our panel for this general guideline (26/26 who

responded to this special vote) till more robust validation become available.

Our final recommendation was to aim for a  $D_{0.03\text{ cc}}$  PRV dose  $\leq 54$  Gy and MAC of 60 Gy.

Level of agreement: 90% (18 of 20 voters) agreed on desirable dose (alternative suggestions ranged from 50-58 Gy); 90% (19 of 21 voters) agreed on MAC (alternative variants proposed ranged from 54-64 Gy).

GRADE of recommendation: High/Moderate

### *Spinal cord*

The QUANTEC review [33] suggests that at 2 Gy per fraction, the probability of myelopathy is 0.03% at 45 Gy and 0.2% at 50 Gy.

Our final recommendation was to aim at a  $D_{0.03\text{ cc}}$  PRV dose  $\leq 45$  Gy and MAC  $\leq 50$  Gy.

Level of agreement: 100% (20 of 20 voters) agreed on desirable dose, 95% (20 of 21 voters) agreed on MAC (alternative variants proposed were up to 55 Gy).

GRADE of recommendation: High

### *Optic chiasm and optic nerve*

The QUANTEC review [34] suggested that the incidence of radiation-induced optic neuropathy (RION) was unusual for a  $D_{\text{max}} < 55$  Gy, particularly for fraction sizes  $< 2$  Gy. The risk increases (3–7%) in the region of 55–60 Gy and becomes more substantial ( $> 7$ –20%) for doses  $> 60$  Gy when fractionation schedules of 1.8–2.0 Gy are used. Similarly, in the study reported by Akagunduz et al. [35], a series of comprehensive visual tests showed that visual field and contrast sensitivity were affected significantly with  $V_{55} \geq 50\%$  and  $D_{\text{mean}} \geq 50$  Gy and visual evoked potential latency was affected significantly with  $D_{\text{mean}} \geq 50$  Gy,  $D_5 \geq 55$  Gy, and  $D_{\text{max}} \geq 60$  Gy. For the chiasm, a significant detrimental effect of all parameters was observed on visual acuity as well.

We set the same dose criteria for both structures as there were no data to suggest that their radiosensitivities were different. However, we suggest separate considerations for according priority levels as discussed above. Our final recommendation was to aim at a  $D_{0.03\text{ cc}}$  PRV

dose  $\leq 54$  Gy and MAC of  $\leq 60$  Gy, for both structures.

Level of agreement: 93% (14 of 15 voters) agreed on desirable dose for the optic chiasm and optic nerve, respectively (alternative variants proposed was 50 Gy). For the recommended MAC, the agreement level among the panel was 82% (14 of 17 voters) and 95% for optic chiasm (alternative variants proposed ranged from 54-56 Gy) and optic nerve (alternative variants proposed were up to 62 Gy), respectively.

GRADE of recommendation: High / Moderate

### *Tumour*

#### *Gross tumour volume (GTV):*

The study by Ng et al. [1], showed that those who received at least 66.5 Gy to primary GTV were less likely to have local failure (odds ratio, 0.289;  $p = 0.020$ ).

Our final recommendation was to aim for a minimum dose of  $\geq 68.6$  Gy (98% dose) and to set a minimum acceptable criterion at 66.5 Gy (95% dose).

Level of agreement: 78% (14 of 18 voters) agreed on desirable dose (alternative variants proposed ranged from 66-70 Gy); 80% (16 of 20 voters) agreed on acceptable dose.

GRADE of recommendation: Moderate

#### *Planning target volume (PTV):*

Dose prescription at 3-4 levels at conventional fractionation was agreed upon by 73%, while 18% would prescribe using 2 dose levels only. As discussed in the previous guideline on the contouring of CTVs [4], we recommend three levels of dose prescription in line with the general principles of ICRU: CTV1 for GTV with margin, CTV2 for high-risk structures/regions, and CTV3 for intermediate-low risk structures/regions for microscopic infiltration. Two commonly used prescription schemes are acceptable: either the 35-fraction (2 Gy per fraction) scheme with doses prescribed to 70, 63-60 and 56 Gy; or the 33-fraction (2.12 Gy per fraction) scheme with the doses prescribed to 69.96, 63-59.4, and 54 Gy. It should be pointed out that current NCCN Guidelines recommend restricting the prescribed dose per fraction to  $\leq 2.12$  Gy due to concerns about risk of excessive damage to adjacent

neurological structures with larger fraction size. [36]

Our final recommendation is to achieve  $\geq 95\%$  dose of the prescribed dose to 100% PTV or  $\geq 93\%$  dose to  $\geq 99\%$  PTV.

Regarding the issue of dose heterogeneity, we recommend restricting hot-spots  $\geq 75$  Gy to  $<10\%$  PTV70 or  $\geq 77$  Gy to  $\leq 5\%$  PTV70 as the preferred criteria; and increased this to  $\geq 75$  Gy to  $<20\%$  PTV70 or  $\geq 77$  Gy to  $\leq 10\%$  PTV70 as the acceptable criteria.

We acknowledge that there is an increasing tendency to accept higher dose heterogeneity and “hot spot” doses to ensure better dose conformality as suggested by the ICRU 83 report [37] or even deliberately giving a higher dose (80 Gy) to certain regions of GTV as a means of dose escalation/dose redistribution according to the tumor behavior as visualized on molecular imaging [38]; but 15% of panel members recommended to control the upper limit of the hot spot dose to not exceed 80 Gy. It is important to emphasize that while there is a move towards higher doses within the target volume these areas should be well away from the critical OAR – especially the brain stem to prevent any untoward neurological adverse events from the treatment itself.

Level of agreement:

- PTV dose prescription: 81% (17 of 21 voters) agreed to either the 35-fraction (2 Gy per fraction) scheme with the doses prescribed to 70, 63-60 and 56 Gy; or the 33-fraction (2.12 Gy per fraction) scheme with the doses prescribed to 69.96, 63-59.4, 54 Gy.
- PTV min: 95% (19 of 20 voters) agreed on desirable dose (alternative variants proposed was aim for 100% of the PTV receiving full prescription dose), 90% (18 of 20 voters) agreed on acceptable dose.
- PTV hotspot: 86% (18 of 21 voters) agreed on desirable dose, 90% (18 of 20 voters) agreed on acceptable dose.

GRADE of recommendation: High/Moderate for PTVmin; Moderate for PTV hotspot

*Temporal lobe:*

The QUANTEC review [39] showed that for conventional fractionation with doses  $\leq 2$  Gy, a

5% risk of symptomatic radiation necrosis is predicted to occur at an equivalent dose of 72 Gy (range, 60–84); furthermore, they cautioned that the brain is especially sensitive to fraction sizes  $>2$  Gy. Due to the close proximity of the temporal lobes to the nasopharynx, multiples studies have been reported in the NPC literature to evaluate the dose-volume effects on temporal lobe injury after IMRT. A study by Sun et al. [40] reported that a  $D_{0.5cc}$  of 69 Gy may be the dose tolerance of the temporal lobe. However, subsequent studies suggested lower dose equivalents of 60.3 Gy ( $D_{2cc}$ ) [41], 62.8 Gy ( $D_{1cc}$ ) [6, 42] and 69 Gy ( $D_{max}$ ) [42] (at 2 Gy/fraction) for a 5% probability of developing temporal lobe injury at 5 years. These findings concurred with a study reported by Su et al. [43], in which the probability of temporal lobe injury was  $\leq 5\%$  at 5 year if  $D_{1cc}$  was less than 58 Gy; and  $D_{max}$  was less than 68 Gy. Furthermore, the volume of temporal lobe receiving low to moderate doses is also an important contributing factor for the development of temporal lobe injury.

On the other hand, for patients with a locally advanced tumor, a reasonable balance between adequate tumor coverage and risk of temporal lobe injury is needed; and a dose limit of  $D_{1cc} \leq 71.14$  Gy [44] and  $D_{max} \leq 72$  Gy [1] have been suggested for T4 disease.

The final recommendation of the panel was to aim for a  $D_{0.03cc}$  PRV dose  $\leq 65$  Gy for T1-2 tumors and  $\leq 70$  Gy for T3-4 tumors; MAC  $\leq 72$  Gy should be confined to T3-4 tumors only. Based on the latest literature findings, we also acknowledge that  $D_{1cc}$  may be a better parameter for future studies.

Level of agreement: 85% (17 of 20 voters) agreed on desirable dose (alternative variants proposed ranged from 66-70 Gy irrespective of the tumour stage); 62% (13 of 21 voters) agreed on MAC dose for T3-4 tumors (alternative variants proposed were up to 74 Gy, but 33% would not accept a MAC  $>70$  Gy).

GRADE of recommendation: Moderate

#### *Brachial plexus:*

Damage to the brachial plexus may have a long latency period of 1 to 17 years (average 8.2 years), but it can lead to significant morbidity of unilateral or bilateral arm or hand paraesthesia, weakness, as well as pain and muscular atrophy [45, 46]. A retrospective study by Cai et al. showed that patients with a therapeutic dose  $\geq 66.8 \pm 2.8$  Gy to lower cervical lymph node metastasis had a significantly higher incidence of radiation-induced brachial

plexopathy [46]. Chen et al. showed that the incidence of brachial plexopathy increased dramatically when  $V_{70}$  exceeds 10% [47]. Thus, the brachial plexus should be outlined as an OAR as a study has shown that a large proportion of patients were exposed to doses exceeding the Radiation Therapy Oncology Group (RTOG) recommended dose constraints when the brachial plexus was not outlined [48]. Placing dose constraints on the brachial plexus can significantly decrease the irradiated volume and dose, without compromising adequate dose delivery to the target volume [49].

In line with the recommendation by RTOG, our final recommendation is to aim at a  $D_{0.03\text{ cc}}$  PRV dose  $\leq 66$  Gy, and MAC of  $\leq 70$  Gy.

Level of agreement: 89% (16 of 18 voters) agreed on desirable dose (alternative variants proposed was  $\leq 60$  Gy); 85% (17 of 20 voters) agreed on acceptable dose (alternative variants proposed was  $\leq 66$  Gy).

GRADE of recommendation: Moderate

#### *Eyeball and lens:*

Jeganathan and colleagues have published an excellent review of ocular risks from orbital and periorbital irradiation [50]. Similar to the considerations for the optic nerve, we would opt to accept exceeding these recommended MACs for ipsilateral structures if necessary, in order to attain adequate tumor dose coverage and the patient has consented to accepting increased risk. The contralateral, less involved side should then be kept within the dose limits.

Our final recommendation of the eyeball was to aim for a mean dose of  $\leq 35$  Gy and MAC of  $D_{0.03\text{ cc}} \leq 50$  Gy. . For the lens, our final recommendation was to aim for a  $D_{0.03\text{ cc}}$  dose  $< 6$  Gy and MAC at  $D_{0.03\text{ cc}}$  dose  $\leq 15$  Gy.

Level of agreement:

- Eyeball: 90% (18 of 20 voters) agreed on desirable dose (alternative variants proposed ranged from 25-45 Gy); 76% (16 of 21 voters) agreed on acceptable dose (alternative variants proposed ranged from 40-60 Gy).

- Lens: 90% (18 of 20 voters) agreed on desirable dose, 82% (18 of 22 voters) agreed on acceptable dose.

GRADE of recommendation: Moderate

*Pituitary (and hypothalamus) and thyroid glands:*

Even in the IMRT era, it has been reported that a significant number of patients, ranging from 20-50%, develop some element of endocrine deficiency post-RT [51-56]. We recommend including the pituitary gland (and hypothalamus) under Priority 3, while setting the thyroid gland as Priority 4, because damage to the thyroid gland will lead to a deficiency of thyroid hormone alone and replacement is possible. In contrast, damage to the pituitary results in complex dysfunction of multiple hormones including sex hormones, cortisol and thyroid pathways, as well as growth hormones.

For the pituitary, we recommend to aim for a  $D_{0.03cc}$  dose  $\leq 60$  Gy and MAC of  $D_{0.03cc}$  dose  $\leq 65$  Gy. However, published data regarding the tolerance of the thyroid gland are scanty. We recommend to aim at  $V_{50} \leq 60\%$ , based on the study by Sachdev et al. (55); and MAC as  $V_{60} \leq 10$  cc.

Level of agreement:

- Pituitary: 79% (11 of 14 voters) agreed on desirable dose (alternative variants proposed ranged from 40-54Gy); 87% (13 of 15 voters) agreed on acceptable dose.
- Thyroid: 88% (14 of 16 voters) agreed on desirable dose (alternative variants proposed were  $D_{0.03cc} \leq 45$  Gy or  $D_{mean} \leq 50$  Gy); 89% (16 of 18 voters) agreed on acceptable dose (alternative variants proposed was  $D_{0.03cc}$  dose  $\leq 50$  Gy).

GRADE of recommendation: Moderate/Low

*Cochlea:*

Due to the location and pattern of invasion of NPC, hearing impairment is one of the commonest toxicities in the IMRT era, especially for those who also receive cisplatin-based chemotherapy. QUANTEC [57] recommends that for conventionally fractionated RT, to minimize the risk for sensorineural hearing loss (SNHL), the mean dose to the cochlea should

be limited to  $\leq 45$  Gy (or more conservatively  $\leq 35$  Gy). Because a threshold for SNHL cannot be determined from the present data, to prevent SNHL the dose to the cochlea should be kept as low as possible. The study by Chan et al. [58] showed that the mean cochlea dose and concurrent cisplatin dose were important determinants of high-frequency SNHL, with an odds ratio of 1.07/Gy increase and 1.008/mg/m<sup>2</sup> increase, respectively; it is thus recommended that the mean MAC to the cochlea should be lowered to  $\leq 47$  Gy for patients treated with chemoradiotherapy. Similar findings have been reported by Wang et al. [59], with an accumulative cisplatin dose of  $\geq 200$  mg/m<sup>2</sup> and radiation dose of 40 Gy to 0.1ml cochlea being predictive factors for the development of SNHL.

Our final recommended dose was to aim for a mean dose of  $\leq 45$  Gy and MAC of mean dose  $\leq 55$  Gy.

Level of agreement: 90% (18 of 20 voters) agreed on desirable dose (alternative variants proposed ranged from 28-50 Gy), 86% (19 of 22 voters) agreed on acceptable dose (alternative variants proposed ranged from 32-52.5Gy).

GRADE of recommendation: Moderate

#### *Parotid gland:*

QUANTEC [60] recommends that severe xerostomia (long-term salivary function  $< 25\%$  of baseline) can usually be avoided if at least one parotid gland has been spared to a mean dose of less than 20 Gy or if both glands have been spared to a mean dose of less than 25 Gy. The study by Lee et al. [61] concurred that with this dose constraint, less than 33% of patients had xerostomia at 3 months and none had it at 12 months. However, this goal might be difficult to achieve, especially with larger tumours and those with gross nodal involvement. A study by Eisbruch et al. [62] reported that partial volume thresholds for prediction of reduced salivary flow were 67%, 45%, and 24% gland volumes receiving more than 15 Gy, 30 Gy, and 45 Gy, respectively, showing substantial preservation of salivary flow rates following RT with continued improvement over time.

Our final recommendation is to aim for a mean dose of  $< 26$  Gy and MAC  $< 30$  Gy for  $\geq 50\%$  of at least 1 gland.

Level of agreement: 90% (18 of 20 voters) agreed on desirable dose (alternative variants proposed being mean dose  $<25\text{Gy}$ ); 82% (18 of 22 voters) agreed on acceptable dose (alternative variants proposed ranged from mean dose  $\leq 25\text{--}35\text{ Gy}$ ).

GRADE of recommendation: Moderate

#### *Mandible and temporomandibular joint (TMJ):*

The mandible and the TMJ are subject to late effects of radiation, leading to possible osteoradionecrosis (ORN) and joint stiffness of the TMJ. A literature review by Mendenhall et al. [63] found that the incidence of ORN is 5% to 10% with a median latency period of 1 to 2 years or less. The likelihood of ORN depends on a number of factors including primary site and extent of disease, dental status, treatment modality, RT dose, volume of mandible included in the planning target volume, RT fractionation schedule and technique, and dental extractions/root canal work.

In the work of Ben-David et al., half of the patients received at least 70 Gy to  $\geq 1\%$  of the mandibular volume; no patients developed  $\geq$  grade 2 ORN [64]. Similarly, Gomez et al. reported that no patients developed ORN using the dose constraint of  $D_{\text{max}} \leq 70\text{ Gy}$ . [65] On the other hand, investigators from the MD Anderson Head and Neck Cancer Working Group reported that the volume effect might be more important than maximum dose. It was found that while the mandibular mean dose was significantly higher in the ORN cohort (48.1 vs 43.6 Gy,  $p < 0.0001$ ), the maximum dose was, in fact, not statistically different. Thus, they recommended  $V_{44} < 42\%$  and  $V_{58} < 25\%$  to the mandible as reasonable DVH constraints for IMRT plan acceptability, when tumour coverage was not compromised [66].

Our final recommendation was to aim for a  $D_{2\%}$  dose of  $\leq 70\text{ Gy}$ , and  $\text{MAC} \leq 75\text{ Gy}$ .

Level of agreement: 95% (18 of 19 voters) agreed on desirable dose, 67% (14 of 21 voters) agreed on acceptable dose (alternative variants proposed ranged narrowly from 73–77 Gy).

GRADE of recommendation: Moderate

#### *Oral cavity:*

Excessively high doses to the oral cavity can result in severe mucositis which can lead to

unscheduled treatment breaks or failure to complete treatment. Both radiotherapy and chemotherapy are independent factors for the risk of incurring acute mucosal toxicities. Sanguineti et al. [67] found that concurrent chemoradiotherapy increases the risk of mucosal Grade 3 toxicity approximately 4 times over RT alone, and it is equivalent to an extra of 6.2 Gy to 21 cc of oral mucosa over a 7-week course. For patients receiving induction chemotherapy followed by chemo-radiation for head and neck cancer, Bhide et al. [68] have derived similar dose response curves. Thus, lower doses to the oral cavity (if achievable) should be considered in patients undergoing concurrent chemo-radiotherapy.

Our final recommendation is to aim for a mean dose of  $\leq 40$  Gy and MAC of  $\leq 50$  Gy.

Level of agreement: 70% (14 of 20 voters) agreed on desirable dose (alternative variants proposed ranged from 35-45 Gy); 77% (17 of 22 voters) agreed on acceptable dose (alternative variants proposed ranged from 30-70 Gy).

GRADE of recommendation: Moderate/Low

#### *Pharynx and constrictor muscles:*

Swallowing problems following RT increase with the addition of concomitant chemotherapy and with increased radiation dose to various structures that are part of the swallowing mechanism [69]. While Feng et al. [70] found that all patients who experienced aspiration as a late complication received mean pharyngeal constrictor doses of  $>60$  Gy or more than 50% of the total pharyngeal constrictor volume received more than 65 Gy ( $V_{65} > 50\%$ ), multiple series have reported a steeper dose effect relationship starting beyond 45 Gy to the pharyngeal wall. [71-73] Levendag et al. [74] showed that a mean dose of 50 Gy predicted a 20% probability of late dysphagia; this probability increased sharply at mean dose  $> 55$  Gy with the chance of dysphagia increasing by 19% with every additional 10 Gy. QUANTEC [75] recommends that with the limited available data available, minimizing the volume of the pharyngeal constrictors and larynx receiving  $\geq 60$  Gy and reducing, when possible, the volume receiving  $\geq 50$  Gy is associated with reduced dysphagia/aspiration.

We recommended a  $D_{\text{mean}} \leq 45$  Gy, and MAC  $\leq 55$  Gy.

Level of agreement: 85% (17 of 20 voters) agreed on desirable dose (alternative variants

proposed ranged from 35-50 Gy); 64% (14 of 22 voters) agreed on acceptable dose (alternative variants proposed ranged widely from 45-70 Gy).

GRADE of recommendation: Moderate/Low

#### *Larynx:*

The study by Vainshtein et al. [76] on voice and speech outcomes after IMRT to the neck region where the larynx is not a target, showed that amongst patients receiving mean glottic larynx (GL) doses of  $\leq 20$  Gy,  $>20$ -30 Gy,  $>30$ -40 Gy,  $>40$ -50 Gy, and  $>50$  Gy; 10%, 32%, 25%, 30%, and 63%, respectively, reported worse voice quality at 12 months compared with pre-treatment status ( $P=.011$ ); similar results were also observed for speech impairment. A study by Rancati et al. [77] on the incidence of subacute or late laryngeal oedema after RT for head and neck cancers showed a clear volume effect consistent with the parallel architecture of the larynx. The authors recommended an equivalent uniform dose of less than 30-35 Gy to reduce the risk of G2-G3 oedema.

Initial proposals based on existing guidelines were to aim for mean dose of  $\leq 45$  Gy and MAC  $\leq 55$  Gy to the glottic larynx in order to reduce adverse effects on speech and voice quality, as well as to avoid laryngeal oedema. However the agreement was only 45% (9/20). Among panellists accustomed to lower neck and supraclavicular conventionally planned fields matched to the IMRT fields (which effectively shield the larynx), their recommendation was to restrict the glottic dose to less than 35 Gy. Basing on the literature of other head and neck, a high proportion of panellists feel that attempts should always be made to minimize the laryngeal mean dose to less than 35 Gy, particularly as this was often achievable even for plans utilising a single whole-neck IMRT field. In a study on oropharyngeal cancers not extending to the larynx, a mean dose of 29 Gy was achievable [78].

Level of agreement: the desirable dose finally recommended is 35 Gy and the agreement was 75% (15 of 20 voters).

GRADE of recommendation: Moderate

#### *Submandibular gland:*

There are scanty data on the tolerance doses of the submandibular gland. A study by

Murdoch-Kinch et al. [79] showed that with mean doses <39 Gy, submandibular gland salivary flow rates recovered over time at 2.2% per month. The unstimulated salivary flow rates decreased exponentially by 3% per Gy increase in mean dose, and this recovered substantially over time if mean dose was <39 Gy. Similarly, Murthy et al. [80] found that the dose tolerance of submandibular gland leading to a 50% complication risk at 1 year was 36 Gy with a 2-2.5% reduction in the probability of severe xerostomia for every 1 Gy reduction in mean dose. QUANTEC [60] recommends that submandibular gland sparing to modest mean doses (<35 Gy) might reduce xerostomia symptoms.

We recommended a mean dose of <35 Gy. No specific recommendation was set for MAC as there is no supporting data in the literature.

Level of agreement: 81% (17 of 21 voters) agreed on desirable dose (alternative variants proposed included a higher dose of < 39 Gy).

GRADE of recommendation: Moderate

#### *Other structures*

##### *Carotid vessels:*

Chu et al. [81] carried out a population-based cohort study based on the claims data of the National Health Research Insurance Database of Taiwan and found that ischaemic stroke incidence rates were 2-fold higher in treated NPC patients than in reference populations, with a greater relative risk in younger patients. While the exact dose tolerances for the carotid vessels have not been well established in the literature, a higher risk of carotid artery stenosis following RT for NPC has been reported [82-85]. Although specific recommendations cannot be made in view of the lack of supporting data; the dose to the carotid vessels should be recorded and kept to as low as reasonably achievable.

No specific recommendation could be made as there is no dose tolerance data in the literature.

## Conclusions

This guideline was derived through extensive review of currently available evidence for setting dose prioritization and acceptance criteria to tumour volumes and OARs, supplemented by an iterative process of guideline development from an international expert panel to put forth best practice recommendations for this complex radiotherapy-treated disease.

When initial variants were circulated among the expert panellists, initial levels of agreement were low for some parameters, such as doses for the larynx and the thyroid. There seemed to be a clear dichotomy between practitioners in the East and West, with Asian experts tending to accept higher doses. Although different interpretations of the evidence will always exist, through iterative voting and revisions to the initially controversial parameters, summary final recommendations were able to be issued by the panel.

The guiding principle should always be ALARP (As Low As Reasonably Practicable), as per radiation safety principles. In cases in which there is difficulty in achieving adequate tumor coverage and doses while respecting the recommended dose constraints, consideration of the relative probability of tumor control balanced against the probabilistic likelihood of normal tissue damage should be undertaken. The current guideline provides a practical reference, although the final decision on the optimal balance of risk and best possible compromises should take into consideration the individual clinical situation and the patient's own preferences. Multicentre collaborations to accumulate more accurate data on the radiation planning factors affecting the therapeutic ratio, identification of clinical and molecular/genetic factors for prediction of radiation sensitivity or resistance, and prospective studies to cautiously explore variants in dose constraints are keenly awaited.

**Supplementary Material (Appendix)**

Supplementary Table 1: Initial recommendations, % agreement and alternative suggestions.

Supplementary Table 2: Quality of evidence and definitions

Supplementary Appendix 1: Literature search summary.

## **References**

1. Ng WT, Lee MC, Chang AT, Chan OS, Chan LL, Cheung FY, et al. The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. *Oral Oncol.* 2014;50(5):506-12.
2. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. *Radiother Oncol.* 2012;104(3):286-93.
3. Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. *Radiother Oncol.* 2014;110(3):377-84.
4. xxxx
5. Chan JW, Parvathaneni U, Yom SS. Reducing radiation-related morbidity in the treatment of nasopharyngeal carcinoma. *Future Oncol.* 2017;13(5):425-31.
6. Zeng L, Huang SM, Tian YM, Sun XM, Han F, Lu TX, et al. Normal Tissue Complication Probability Model for Radiation-induced Temporal Lobe Injury after Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma. *Radiology.* 2015;276(1):243-9.
7. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. *BMC Cancer.* 2013;13:397.
8. Bhandare N, Mendenhall WM. A Literature Review of Late Complications of Radiation Therapy for Head and Neck Cancers: Incidence and Dose Response. *J Nucl Med Radiat Ther* 2012 S2:009.
9. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative

Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys.* 2010;76(3 Suppl):S3-9.

10. Ng WT, Lee MC, Hung WM et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2011, 79(2):420-428.

11. Ng WT, RK Ngan, SH Chan, et al. Management of nasopharyngeal carcinoma. In: J. Bernier (ed.). *Head and Neck Cancer - Multimodality Management*. 2nd ed. Switzerland: Springer; 2016.

12. 2010 Nasopharyngeal Carcinoma Intensity Modulated Radiotherapy Target and Dose Design Guidelines. Expert consensus. *Chin J Radiat Oncol*, 2011,20(04): 267-269. (Article in Chinese) <http://zhfszlxzz.yiigle.com/CN11303020112004/424433.htm>

13. Merlotti A, Alterio D, Vigna-Taglianti R et al: Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. *Radiat Oncol* 2014, 9:264.

14. DAHANCA Radiotherapy Guidelines 2013.  
<https://www.dahanca.oncology.dk/uploads/DAHANCA%20Radiotherapy%20Guidelines%202013%20English%20%200%20jan%202015.pdf>

15. Dose Objectives for Head and Neck IMRT Treatment Planning. Recommendation Report: A project developed by the Head and Neck Community of Practice of the Radiation Treatment Program of Cancer Care Ontario for circulation to Regional Cancer Programs.  
<https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/3186>

16. Lee N, Harris J, Garden AS et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II trial 0225. *J Clin Oncol* 2009, 27(22):3684-3690.

17. Lee NY, Zhang Q, Pfister DG et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-

institutional trial. *Lancet Oncol* 2012, 13(2):172-180.

18. NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA). <https://www.nrgoncology.org/Clinical-Trials/Protocol-Table>

19. Huang XD, Li YC, Chen FP, et al: Evolution and Dosimetric Analysis of MRI-detected Brainstem Injury Following Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* 2019. May 7. pii: S0360-3016(19)30694-7. doi: 10.1016/j.ijrobp.2019.04.032. [Epub ahead of print]

20. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008 Apr 26;336(7650):924-6.

21. xxxx

22. xxxx

23. van Herk M. Errors and margins in radiotherapy. *Semin Radiat Oncol*. 2004 Jan;14(1):52-64.

24. Yao JJ, Chen FP, Zhou GQ, et al. A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. *Oncotarget*. 2016 Apr 19;7(16):21742-52.

25. Yang H, Chen X, Lin S et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. *Radiother Oncol*. 2018 Jan;126(1):37-42

26. Lam TC, Wong FC, Leung TW, Ng SH, Tung SY. Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. *Int J Radiat Oncol Biol Phys*. 2012 Jan 1;82(1):e57-65.

27. Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1;76(3 Suppl):S36-41.
28. Li YC, Chen FP, Zhou GQ, Zhu JH, Hu J, Kang DH et al. Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma. *Oral Oncol.* 2017 Oct;73:97-104
29. Yao CY, Zhou GR, Wang LJ et al. A retrospective dosimetry study of intensity-modulated radiotherapy for nasopharyngeal carcinoma: radiation-induced brainstem injury and dose-volume analysis. *Radiat Oncol.* 2018 Oct 3;13(1):194.
30. Uy NW, Woo SY, The BS, et al. Intensity-modulated radiation therapy (IMRT) for meningioma. *Int J Radiat Oncol Biol Phys.* 2002 Aug 1;53(5):1265-70.
31. Debus J, Hug EB, Liebsch NJ, O'Farrel D, Finkelstein D, Efird J et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. *Int J Radiat Oncol Biol Phys.* 1997 Dec 1;39(5):967-75.
32. Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. *Int J Radiat Oncol Biol Phys.* 2008 Jun 1;71(2):377-8533. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1;76(3 Suppl):S42-9.
34. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1;76(3 Suppl):S28-35
35. Ozkaya Akagunduz O, Guven Yilmaz S, Yalman D, et al. Evaluation of the Radiation Dose-Volume Effects of Optic Nerves and Chiasm by Psychophysical, Electrophysiologic Tests, and Optical Coherence Tomography in Nasopharyngeal Carcinoma. *Technol Cancer Res Treat.* 2017 Jan 1
36. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)

37. <https://icru.org/testing/reports/prescribing-recording-and-reporting-intensity-modulated-photon-beam-therapy-imrt-icru-report-83>
38. Grégoire V, Thorwarth D, Lee JA. Molecular Imaging-Guided Radiotherapy for the Treatment of Head-and-Neck Squamous Cell Carcinoma: Does it Fulfill the Promises? *Semin Radiat Oncol*. 2018 Jan;28(1):35-45.
39. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE et al. Radiation dose-volume effects in the brain. *Int J Radiat Oncol Biol Phys*. 2010 Mar 1;76(3 Suppl):S20-7
40. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. *BMC Cancer*. 2013;13:397.
41. Feng M, Huang Y, Fan X, Xu P, Lang J, Wang D. Prognostic variables for temporal lobe injury after intensity modulated-radiotherapy of nasopharyngeal carcinoma. *Cancer Med*. 2018 Mar;7(3):557-564
42. Kong C, Zhu XZ, Lee TF et al. LASSO-based NTCP model for radiation-induced temporal lobe injury developing after intensity-modulated radiotherapy of nasopharyngeal carcinoma. *Sci Rep*. 2016 May 23;6:26378
43. Su SF, Huang Y, Xiao WW et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. *Radiother Oncol*. 2012 Sep;104(3):312-6.
44. Huang J, Kong FF, Oei RW, Zhai RP, Hu CS, Ying HM. Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study. *Radiat Oncol*. 2019 Feb 8;14(1):31.
45. Gu B, Yang Z, Huang S, Xiao S, Zhang B, Yang L et al. Radiation-induced brachial plexus injury after radiotherapy for nasopharyngeal carcinoma. *Jpn J Clin Oncol*. 2014

*Aug;44(8):736-42.*

46. Cai Z, Li Y, Hu Z, Fu R, Rong X, Wu R et al. Radiation-induced brachial plexopathy in patients with nasopharyngeal carcinoma: a retrospective study. *Oncotarget*. 2016 Apr 5; 7(14): 18887–18895.

47. Chen AM, Wang PC, Daly ME, et al. Dose--volume modeling of brachial plexus-associated neuropathy after radiation therapy for head-and-neck cancer: findings from a prospective screening protocol. *Int J Radiat Oncol Biol Phys*. 2014 Mar 15; 88(4):771-7.

48. Feng G, Lu H, Liang Y, Chen H, Shu L, Lu S et al. Radiation dose to the brachial plexus in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: An increased risk of an excessive dose to the brachial plexus adjacent to gross nodal disease. *Exp Ther Med*. 2012 Aug;4(2):216-220.

49. Jiang H, Lu H, Yuan H, Huang H, Wei Y, Zhang Y, Liu X et al. Dosimetric benefits of placing dose constraints on the brachial plexus in patients with nasopharyngeal carcinoma receiving intensity-modulated radiation therapy: a comparative study. *J Radiat Res*. 2015 Jan;56(1):114-21.

50. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. *Int J Radiat Oncol Biol Phys*. 2011 Mar 1; 79(3):650-9.

51. Huang S, Wang X, Hu C, Ying H. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. *Med Oncol*. 2013;30(4):710.

52. Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, et al. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2017;98(3):574-80.

53. Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, et al. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. *Clin Oncol (R Coll Radiol)*. 2016;28(8):e52-60.

54. Zhai RP, Kong FF, Du CR, Hu CS, Ying HM. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study. *Oral Oncol.* 2017;68:44-9.
55. Luo R, Li M, Yang Z, Zhan Y, Huang B, Lu J, et al. Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment. *Br J Radiol.* 2017;90(1070):20160686.
56. Sachdev S, Refaat T, Bacchus ID, Sathiaselan V, Mittal BB. Thyroid V50 Highly Predictive of Hypothyroidism in Head-and-Neck Cancer Patients Treated With Intensity-modulated Radiotherapy (IMRT). *Am J Clin Oncol.* 2017 Aug;40(4):413-417.
57. Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P et al. Radiation therapy and hearing loss. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1;76(3 Suppl):S50-7.
58. Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. *Int J Radiat Oncol Biol Phys.* 2009 Apr 1;73(5):1335-42.
59. Wang J, Chen YY, Tai A et al. Sensorineural Hearing Loss after Combined Intensity Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma. *Transl Oncol.* 2015 Dec;8(6):456-62
60. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1;76(3 Suppl):S58-63.
61. Lee TF, Fang FM. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. *Radiother Oncol.* 2013;106(3):352-8.
62. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function

relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. *Int J Radiat Oncol Biol Phys.* 1999;45(3):577-87.

63. Mendenhall WM, Suarez C, Genden EM, de Bree R, Strojan P, Langendijk JA, et al. Parameters Associated With Mandibular Osteoradionecrosis. *Am J Clin Oncol.* 2018 Dec;41(12):1276-1280.

64. Ben-David MA, Diamante M, Radawski M, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. *Int J Radiat Oncol Biol Phys.* 2007 Jun 1; 68(2):396-402. Epub 2007 Feb 22.

65. Gomez DR, Estilo CL, Wolden SL, et al. Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity- modulated radiation therapy for head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2011; 81:e207-e213.

66. MD Anderson Head and Neck Cancer Working Group. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. *Radiother Oncol.* 2017;124(2):232-

67. Sanguineti G, Sormani MP, Marur S, Gunn GB, Rao N, Cianchetti M, et al. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. *Int J Radiat Oncol Biol Phys.* 2012;83(1):235-42.

68. Bhide SA, Gulliford S, Schick U, Miah A, Zaidi S, Newbold K, et al. Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. *Radiother Oncol.* 2012 Apr;103(1):88-91.

69. Paleri V, Roe JW, Strojan P, Corry J, Grégoire V, Hamoir M et al. Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. *Head Neck.* 2014 Mar;36(3):431-43.

70. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck

cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. *Int J Radiat Oncol Biol Phys* 2007; 68:1289–1298.

71. Doornaert P, Slotman BJ, Rietveld DHF, et al. The mean radiation dose in pharyngeal structures is a strong predictor of acute and persistent swallowing dysfunction and quality of life in head and neck radiotherapy. *Int J Radiat Oncol Biol Phys* 2007; 69(Suppl):55.

72. Caglar HB, Allen AM, Othus M, et al. Dose to the larynx predicts for swallowing complications following IMRT and chemotherapy. *Int J Radiat Oncol Biol Phys* 2008;72:1110–1118.

73. O'Meara EA, Machtay M, Moughan J, et al. Association between radiation doses to pharyngeal regions and severe late toxicity in head and neck cancer patients treated with concurrent chemoradiotherapy—An RTOG analysis. *Int J Radiat Oncol Biol Phys* 2007;69(Suppl):54.

74. Levendag PC, Teguh DN, Voet P. et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. *Radiother Oncol* 2007;85:64–73.

75. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B et al. Radiation dose-volume effects in the larynx and pharynx. *Int J Radiat Oncol Biol Phys*. 2010 Mar 1;76(3 Suppl):S64-9.

76. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. *Int J Radiat Oncol Biol Phys*. 2014;89(5):973-80.

77. Rancati T, Fiorino C, Sanguineti G. NTCP modeling of subacute/late laryngeal edema scored by fiberoptic examination. *Int J Radiat Oncol Biol Phys*. 2009;75(3):915-23.

78. Webster GJ, Rowbottom CG, Ho KF, Slevin NJ, Mackay RI. Evaluation of larynx-sparing techniques with IMRT when treating the head and neck. *Int J Radiat Oncol Biol Phys*. 2008

*Oct 1;72(2):617-22.*

79. Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A. Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. *Int J Radiat Oncol Biol Phys.* 2008;72(2):373-82.

80. Murthy V, Lewis S, Kannan S, Khadanga CR, Rangarajan V, Joshi K et al. Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study. *Radiother Oncol.* 2018 Oct;129(1):38-43.

81. Chu CN, Chen PC, Bai LY, Muo CH, Sung FC, Chen SW. Young nasopharyngeal cancer patients with radiotherapy and chemotherapy are most prone to ischaemic risk of stroke: a national database, controlled cohort study. *Clin Otolaryngol.* 2013;38(1):39-47.

82. Steele SR, Martin MJ, Mullenix PS, Crawford JV, Cuadrado DS, Andersen CA. Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer. *Am J Surg.* 2004;5:594-598.

83. Lam WW, Leung SF, So NM, Wong KS, Liu KH, Ku PK, Yuen HY, Metreweli C. Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. *Cancer.* 2001;92:2357-2363.

84. Cheng SW, Ting AC, Lam LK, Wei WI. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. *Arch Otolaryngol Head Neck Surg.* 2000;126:517-521.

85. Huang TL, Hsu HC, Chen HC, Lin HC, Chien CY, Fang FM, Huang CC, Chang HW, Chang WN, Huang CR, et al. Long-term effects on carotid intima-media thickness after radiotherapy in patients with nasopharyngeal carcinoma. *Radiat Oncol.* 2013;8:261.

|                | NPC-specific protocol            |                        |                           |                          |                     |            |                          | H&N protocol               |                        |               |        |                        |
|----------------|----------------------------------|------------------------|---------------------------|--------------------------|---------------------|------------|--------------------------|----------------------------|------------------------|---------------|--------|------------------------|
|                | HKU/ PYNEH (10,11) PYNEH (10,11) |                        | RTOG 0225 (16)            | RTOG 0615 (17)           | NRG HN001 (18)      |            | China (12)               | AIRO (13)                  |                        | DAHANCA (14)  |        | Ontario (15)           |
|                | Goal                             | Acceptable             |                           |                          | Goal                | Acceptable |                          | Goal                       | Acceptable             | OAR           | PRV    |                        |
| Brainstem      | Max                              |                        | Max                       | Max                      | 0.03 cc             |            | Max                      | Max                        |                        | Max           |        | Max                    |
|                | ≤54 Gy                           | ≤60 Gy (For T3-4 only) | ≤54 Gy or ≤1% vol. >60 Gy | ≤54 Gy or ≤1% PRV >60 Gy | <54 Gy              | ≤60 Gy     | ≤54 Gy ≤1% PRV >60 Gy    | ≤54 Gy                     | ≤60 Gy                 | ≤54 Gy        | ≤60 Gy | ≤54 Gy or 0.1cc ≤50 Gy |
| Spinal cord    | Max                              |                        | Max                       | Max                      | 0.03 cc             |            | Max                      | Max                        |                        | Max           |        | Max                    |
|                | ≤45 Gy                           | ≤50 Gy (For T3-4 only) | 45 Gy or ≤1cc vol. >50 Gy | ≤45 Gy or ≤1% PRV >50 Gy | <45 Gy              | ≤50 Gy     | ≤45 Gy or ≤1% PRV >50 Gy | ≤44-45 Gy or PRV ≤44-48 Gy | 46 Gy or PRV ≤48-50 Gy | ≤45 Gy        | ≤50 Gy | ≤48 Gy or 0.1cc ≤45 Gy |
| Optical chiasm | Max                              |                        | Max                       | Max                      | 0.03 cc             |            | Max                      | Max (PRV)                  |                        | Max           |        | Max                    |
|                | ≤54 Gy                           | ≤60 Gy (For T3-4 only) | 54 Gy or ≤1% vol. >60 Gy  | ≤50 Gy or PRV ≤54 Gy     | <54 Gy              | ≤56 Gy     | ≤50 Gy or PRV ≤55 Gy     | ≤54 Gy                     | Max ≤60 Gy             | ≤54 Gy        | ≤60 Gy | ≤50 Gy                 |
| GTV-T & GTV-N  | Min                              |                        | Not stated                | Not stated               | Not stated          | Not stated | Not stated               | Not stated                 |                        | Not stated    |        | Not stated             |
|                | ≥68.6 Gy (98% dose)              | ≥66.5 Gy (95% dose)    |                           |                          |                     |            |                          |                            |                        |               |        |                        |
| CTV min        | Not stated                       |                        | Not stated                | Not stated               | CTV6996 - 99 % vol. |            | Not stated               | Not stated                 |                        | CTV1          |        | Not Stated             |
|                |                                  |                        |                           |                          | >65.1 Gy 65.1–60 Gy |            |                          |                            |                        | 95%-107% dose |        |                        |
|                |                                  |                        |                           |                          | CTV6270 - 99 % vol. |            |                          |                            |                        | CTV2 & CTV3   |        |                        |

|                       |                      |                              |                                     |            |                                                    |                                                                                            |                                                      |                                               |            |                    |                                                |
|-----------------------|----------------------|------------------------------|-------------------------------------|------------|----------------------------------------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|------------|--------------------|------------------------------------------------|
|                       |                      |                              |                                     |            |                                                    | >58.6 Gy;<br>CTV5940<br>- 99 %<br>vol.<br>>55.2 Gy<br>CTV5412<br>- 99 %<br>vol<br>>50.2 Gy | 58.6–55 Gy<br><br>55.2–52 Gy<br><br>50.2–45 Gy       |                                               |            | 95% doses          |                                                |
| CTV Hotspot           |                      |                              |                                     |            |                                                    |                                                                                            |                                                      |                                               |            | ≤1.8 cc >107% CTV1 |                                                |
| PTV dose prescription | PTV70, 63, 56        |                              | PTV70, 59.4                         |            | PTV70                                              | PTV6996                                                                                    |                                                      | PTV70                                         |            |                    | PTV70, 63, 56                                  |
| PTV min               | 100% PTV             | ≥95% PTV<br>100% dose        | ≥99% PTV                            | 95-98% PTV | ≥95% PTV<br>100% dose                              | ≥95% PTV* 100% dose                                                                        |                                                      | ≥99% PTV<br>≥93% dose                         | Not stated | 100% PTV           | ≥99 % PTV 100% dose                            |
|                       | ≥95% dose            |                              | ≥93% dose                           | ≥93% dose  | PTV63, 59.4,54                                     | PTV 6270, 5940, 5412                                                                       |                                                      |                                               |            | ≥95% dose          | or ≥99 % PTV ≥95% dose                         |
|                       |                      | or ≥99% PTV<br><br>≥93% dose |                                     |            | ≥95% PTV<br>100% dose<br><br>≥99% PTV<br>≥93% dose | ≥95% PTV<br>≥95% dose                                                                      | ≥95% PTV*<br>100% dose<br><br>≥90% PTV*<br>100% dose |                                               |            |                    |                                                |
| PTV Hotspot           | <10% PTV70<br>≥75 Gy | <2% PTV70 ≥77 Gy             | ≤20% PTV70<br>≥77 Gy<br>(110% dose) |            | ≤20% PTV70<br>≥77 Gy<br><br>≤5% PTV70<br>≥80 Gy    | ≤ 40% PTV<br>≥77 Gy<br><br>≤ 20% PTV<br>≥ 80 Gy                                            | 0.03 cc<br><br>0.03 cc<br><br>≤80.5 Gy<br>80.5–84 Gy | <20% PTV<br>≥77 Gy<br><br><5% PTV<br>≥80.5 Gy |            |                    | <20% PTV1 ≥77 Gy<br><br>Max mean dose ≤73.5 Gy |
| Optic nerve           | Max                  |                              | Max                                 |            | Max                                                | 0.03 cc                                                                                    |                                                      | Max                                           | Max (PRV)  | Max                | Max                                            |

[illegible]

|                                                |        |        |            |            |            |        |                                                                |                   |                                     |                                                          |
|------------------------------------------------|--------|--------|------------|------------|------------|--------|----------------------------------------------------------------|-------------------|-------------------------------------|----------------------------------------------------------|
| Pituitary                                      | Max    |        |            |            |            | Mean   | Max                                                            |                   | Mean                                |                                                          |
|                                                | ≤60 Gy | ≤65 Gy | Not stated | Not stated | Not stated | ≤50 Gy | ≤50 Gy                                                         |                   | ≤30 Gy                              |                                                          |
| Lens                                           | Max    |        |            | Max        | 0.03 cc    | Max    | Max                                                            |                   | Not stated                          | Max                                                      |
|                                                | ≤6 Gy  | ≤10 Gy | Not stated | < 25 Gy    | <15 Gy     | ≤25 Gy | <4 Gy                                                          | <6 Gy             |                                     | ≤5 Gy                                                    |
| Eyeball                                        | Max    | Mean   | Mean       | Max        | 0.03 cc    | Max    | Retina - Max                                                   |                   | Max                                 | Max                                                      |
|                                                | ≤50 Gy | <35 Gy | <35 Gy     | <50 Gy     | <55 Gy     | ≤50 Gy | ≤54 Gy                                                         | ≤60 Gy            | Retina: ≤45 Gy; Other parts: ≤30 Gy | Retina: ≤50 Gy; Other parts: ≤35 Gy                      |
| Cochlea                                        | Mean   |        | Mean       | ≤5% vol.   | 0.03 cc    | Mean   | Mean                                                           |                   | Mean                                | Max                                                      |
|                                                | <50 Gy | ≤55 Gy | <50 Gy     | ≥55 Gy     | ≤55 Gy     | ≤45 Gy | <50 Gy                                                         | <52.5 Gy          | ≤45 Gy or ≤5% vol. ≥55 Gy           | ≤45 Gy                                                   |
| Glottic larynx                                 | Mean   |        | Mean       | Mean       | Mean       | Mean   | Max                                                            |                   | Mean                                | Mean                                                     |
|                                                | <45 Gy |        | <45 Gy     | <45 Gy     | <40 Gy     | ≤45 Gy | supraglottis < 66 Gy; whole larynx: <50 Gy; or ≤25% vol.>50 Gy |                   | ≤44 Gy                              | ≤45 Gy or ≤67% vol. >50 Gy                               |
| Post-cricoid pharynx, esophagus (within field) | Mean   |        |            | Mean       | Mean       | Mean   | Max                                                            |                   | Mean                                | Mean                                                     |
|                                                | <45 Gy |        | Not stated | <45 Gy     | <50 Gy     | ≤45 Gy | Esophagus: ≤45 Gy; pharyngeal constrictor muscle: ≤50 Gy       | Esophagus: <55 Gy | ≤ 30 Gy                             | Esophagus: ≤45 Gy; pharyngeal constrictor muscle: ≤50 Gy |
| Oral cavity                                    | Mean   |        | Max        | Mean       | Mean       | Mean   |                                                                |                   | Mean                                | Mean                                                     |

|  |            |            |            |            |        |       |
|--|------------|------------|------------|------------|--------|-------|
|  |            | Mean       | Mean       |            | Mean   |       |
|  | Not stated | <35 Gy     | <35 Gy     | Not stated | <35 Gy | Not s |
|  | Not stated | Not stated | Not stated |            | Mean   |       |
|  | Not stated | Not stated | Not stated |            | ≤20 Gy | Not s |
|  |            |            |            |            |        |       |

| Organ at Risk (OAR)   |                      |                                 |                                                       | Acceptance Criteria |                                                        |                                 |                                           |                                 |                         |
|-----------------------|----------------------|---------------------------------|-------------------------------------------------------|---------------------|--------------------------------------------------------|---------------------------------|-------------------------------------------|---------------------------------|-------------------------|
|                       |                      |                                 |                                                       |                     | Desirable Dose                                         |                                 | Acceptable Dose                           |                                 |                         |
| Organ                 | Priority             | % Agree<br>(of those who voted) | Disagree<br>(alternative priority) –<br>Number voting | Specification       | Dose                                                   | % agree<br>(of those who voted) | Dose                                      | % agree<br>(of those who voted) | GRADE of recommendation |
| Brainstem             | 1                    | 17/17<br>100%                   |                                                       | D0.03 cc            | ≤54 Gy                                                 | 18/20<br>90%                    | ≤60 Gy <sup>#</sup>                       | 19/21<br>90%                    | High/Moderate           |
| Spinal cord           | 1                    | 17/17<br>100%                   |                                                       | D0.03 cc            | ≤45 Gy                                                 | 20/20<br>100%                   | ≤50 Gy                                    | 20/21<br>95%                    | High                    |
| Optic chiasm          | 1                    | 16/17<br>94%                    | (3) – 1/17                                            | D0.03 cc            | ≤54 Gy                                                 | 14/15<br>93%                    | ≤60 Gy                                    | 14/17<br>82%                    | High/Moderate           |
| GTV-T & GTV-N         | 2                    | 10/16<br>63%                    | (1) – 6/16                                            | Min                 | ≥68.6 Gy (98% dose)                                    | 14/18<br>78%                    | 66.5 Gy (95% dose)                        | 16/20<br>80%                    | Moderate                |
| PTV dose prescription | 2                    | 15/17<br>88%                    | (1) – 1/17<br>(4) – 1/17                              | Prescription dose   | PTV70, 63, 60, 56 = 35#<br>PTV 69.96, 63, 60, 54 = 33# | 17/21<br>81%                    |                                           |                                 |                         |
| PTV min               | 2                    | 13/15<br>87%                    | (1) – 1/15<br>(4) – 1/15                              | Min                 | ≥95% PTV 100% or<br>≥99% PTV ≥93% dose                 | 19/20<br>95%                    | 95% PTV ≥ 95% dose                        | 18/20<br>90%                    | High / Moderate         |
| PTV hotspot           | 2                    | 14/15<br>93%                    | (4) – 1/15                                            | Max                 | <5% PTV70 ≥ 75 Gy or<br>≤10% PTV70 ≥77 Gy              | 18/21<br>86%                    | <10% PTV70 ≥75 Gy or<br>≤20% PTV70 ≥77 Gy | 18/20<br>90%                    | Moderate                |
| Temporal lobe         | 2                    | 11/17<br>65%                    | (1) – 1/17<br>(3) – 4/17<br>(5) – 1/17                | D0.03 cc            | ≤65 Gy for early stage and<br>≤70 Gy for late stage    | 17/20<br>85%                    | ≤72 Gy                                    | 13/21<br>62%                    | Moderate                |
| Optic nerve           | 3<br>Bilateral:<br>1 | 12/17<br>71%                    | (1) – 2/17<br>(2) – 2/17<br>(3) – 1/17                | D0.03 cc            | ≤54 Gy                                                 | 19/20<br>95%                    | ≤60 Gy                                    | 21/22<br>95%                    | High / Moderate         |
| Parotid gland         | 4                    | 12/17<br>71%                    | (2) – 2/17<br>(3) – 2/17<br>(5) – 1/17                | Mean                | <26 Gy                                                 | 18/20<br>90%                    | <30 Gy (at least one gland)               | 18/22<br>82%                    | Moderate                |

|                                                       |          |              |                                        |                 |                      |              |                            |              |                |
|-------------------------------------------------------|----------|--------------|----------------------------------------|-----------------|----------------------|--------------|----------------------------|--------------|----------------|
| <b>Mandible &amp; TM joint</b>                        | <b>4</b> | 14/17<br>82% | (3) – 2/17<br>(5) – 1/17               | <b>D2%</b>      | ≤70 Gy               | 18/19<br>95% | ≤75 Gy                     | 14/21<br>67% | Moderate       |
| <b>Brachial plexus</b>                                | <b>3</b> | 13/15<br>87% | (2) – 1/15<br>(5) – 1/15               | <b>D0.03 cc</b> | <66 Gy               | 16/18<br>89% | ≤70 Gy                     | 17/20<br>85% | Moderate       |
| <b>Pituitary</b><br>(and hypothalamus)                | <b>4</b> | 11/14<br>79% | (2) – 1/14<br>(3) – 1/14<br>(5) – 1/14 | <b>D0.03 cc</b> | ≤60 Gy               | 11/14<br>79% | ≤65 Gy                     | 13/15<br>87% | Moderate / Low |
| <b>Lens</b>                                           | <b>3</b> | 12/17<br>71% | (1) – 1/17<br>(4) – 2/17<br>(5) – 2/17 | <b>D0.03 cc</b> | ≤6 Gy                | 18/20<br>90% | ≤15 Gy                     | 18/22<br>82% | Moderate       |
| <b>Eyeball</b>                                        | <b>3</b> | 14/17<br>82% | (2) – 2/17<br>(4) – 1/17               | <b>Mean</b>     | <35 Gy               | 18/20<br>90% | ≤50 Gy ( <b>D0.03 cc</b> ) | 16/21<br>76% | Moderate       |
| <b>Cochlea</b>                                        | <b>4</b> | 13/17<br>76% | (2) – 2/17<br>(3) – 2/17               | <b>Mean</b>     | ≤45 Gy               | 18/20<br>90% | ≤55 Gy                     | 19/22<br>86% | Moderate       |
| <b>Glottic larynx</b>                                 | <b>4</b> | 16/17<br>94% | (3) – 1/17                             | <b>Mean</b>     | ≤35 Gy               | 15/20<br>75% | ≤50 Gy ( <b>D2%</b> )      | 10/22<br>45% | Moderate       |
| <b>Post-cricoid pharynx, esophagus (within field)</b> | <b>4</b> | 13/17<br>76% | (3) – 2/17<br>(5) – 2/17               | <b>Mean</b>     | ≤45 Gy               | 17/20<br>85% | ≤55 Gy                     | 14/22<br>64% | Moderate / Low |
| <b>Oral cavity (excluding PTV)</b>                    | <b>4</b> | 13/17<br>76% | (3) – 2/17<br>(5) – 2/17               | <b>Mean</b>     | <40 Gy               | 14/20<br>70% | <50 Gy                     | 17/22<br>77% | Moderate / Low |
| <b>Submandibular gland</b>                            | <b>4</b> | 13/14<br>93% | (5) – 1/14                             | <b>Mean</b>     | <35 Gy               | 17/21<br>81% |                            |              | Moderate       |
| <b>Thyroid</b>                                        | <b>4</b> | 12/14<br>86% | (3) – 1/14<br>(5) – 1/14               |                 | V <sub>50</sub> <70% | 14/16<br>88% | VS <sub>60</sub> > 10cc    | 16/18<br>89% | Moderate / Low |

Table 2. OAR prioritization and Acceptance Criteria - final agreement results.

<sup>#</sup>A recent study by Huang et al [19] suggested  $D_{\max}$  of 67.4 Gy (equivalent dose in 2-Gy fractions) as the dose constraint for brainstem. While this may be discussed as an option for patients with tumors encroaching the brainstem, a conservative dose acceptance criterion (to aim for a  $D_{0.03\text{ cc}}$  PRV dose  $\leq 54$  Gy and MAC of 60 Gy) was preferred among our panel (25/25 [100%] of those who responded to this special vote) for this general guideline till more robust validation become available.